Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (β-SPECIFIC 2)

This study has been completed.
Sponsor:
Collaborator:
Pediatric Rheumatology International Trials Organization
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00889863
First received: April 21, 2009
Last updated: September 13, 2012
Last verified: September 2012

April 21, 2009
September 13, 2012
July 2009
September 2011   (final data collection date for primary outcome measure)
  • Part I: Percentage of Patients Who Were on Steroids at Entry Into Part I and Who Were Able to Taper Steroid as Per Protocol in at Least 25% of the Patients Who Entered the Study Taking a Steroid [ Time Frame: 32 Weeks ] [ Designated as safety issue: No ]
    Ability to taper oral steroids: if dose reduced from start of Part I to end of Part Ic from > 0.8 mg/kg/day to ≤ 0.5 mg/kg/day, or from ≥ 0.5 mg/kg/day and ≤ 0.8 mg/kg/day by at least 0.3 mg/kg, or from any initial dose to ≤ 0.2 mg/kg/day, while maintaining a minimum adapted ACR 30 pediatric criterion. Patients on oral steroids at study entry who did not enter Part 1c are considered steroid tapering failures.
  • Part II: Survival Estimate of Time to Flare [ Time Frame: Part II was event driven. The study was stopped when the required number of 37 flares had occurred (88 weeks) ] [ Designated as safety issue: No ]

    Kaplan Meier estimate of the probability to experience a flare. Flare was defined as at least 1 of the following.

    • Reappearance of fever (>38°C, lasting for at least 2 consecutive days) not due to infections
    • Flare according to the JIA pediatric criteria for flare (all criteria must have been met):
    • ≥ 30% worsening in at least 3 of the first 6 response variables
    • ≥ 30% improvement in not more than 1 of the first 6 response variables Patients who discontinued the study while in Part II were counted as flared unless they discontinued because of inactive disease for at least 24 weeks in Part II.
  • Proportion of patients who were on steroids at entry into Part I and who were able to taper steroid as per protocol. [ Time Frame: Maximun duration of Part I 32 weeks ] [ Designated as safety issue: No ]
  • Time to flare in Part II [ Time Frame: During part II, which is event driven (total duration - TBD) ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00889863 on ClinicalTrials.gov Archive Site
  • Part I: Percentage of Patients on Steroids at Study Start Who Reached a Steroid Dose ≤0.2 mg/kg at End of Part Ic [ Time Frame: 28 Weeks ] [ Designated as safety issue: No ]
  • Part I: Percentage of Participants on Steroids at the Start of 1c Who Were Able to Taper Steroids by the End of Part 1c [ Time Frame: Start of Part Ic (After Week 8) to End of Part Ic (Week 28) ] [ Designated as safety issue: No ]
  • Part I: Percentage of Participants With Minimum American College of Rheumatology (ACR) 30/50/70/90/100 at the End of Part I [ Time Frame: Baseline, 32 Weeks ] [ Designated as safety issue: No ]

    Adapted ACR Pediatric 30/50/70/90/100 criteria are defined as meeting all of the following:

    • improvement from baseline of ≥ 30%, ≥ 50%, ≥ 70%, ≥ 90%, or 100%, in at least 3 of the first 6 response variables

      1. Physician's global assessment of disease activity
      2. CHAQ-patient's overall well-being
      3. CHAQ-Functional ability
      4. # of joints with active arthritis
      5. # of joints with limitation of motion
      6. C-Reactive Protein.
    • no intermittent fever in the preceding week
    • no more than one of the first 6 response variables worsening by more than 30%
  • Part I: Time to First Minimum American College of Rheumatology (ACR50) and Normal C-Reactive Protein [ Time Frame: Baseline, Week 32 ] [ Designated as safety issue: No ]
    Duration in days in the study to the first minimum adapted ACR Pediatric 50 criteria and a normal (<10mg/L) C-Reactive Protein
  • Part I: Time to First Minimum American College of Rheumatology (ACR70) and Normal C-Reactive Protein [ Time Frame: Baseline, Week 32 ] [ Designated as safety issue: No ]
    Duration in days in the study to the first minimum adapted ACR Pediatric 70 criteria and a normal (<10mg/L) C-Reactive Protein
  • Part I: Percentage of Participants With Body Temperature ≤ 38 Degrees Celsius at Day 3 in Part 1a [ Time Frame: Day 3 ] [ Designated as safety issue: No ]
  • Part II: Survival Analysis of Time to a Worsening in American College of Rheumatology (ACR) Response [ Time Frame: Part II was event driven. The study was stopped when the required number of 37 flares had occurred (88 weeks) ] [ Designated as safety issue: No ]

    Kaplan Meier estimate of the time in days to the probability of worsening of the ACR response.

    ACR response is determined by the following items:

    1. Physician's global assessment of disease activity
    2. CHAQ-patient's overall wellbeing
    3. CHAQ-Functional ability
    4. Number of joints with active arthritis
    5. Number of joints with limitation of motion
    6. C-Reactive Protein.
    7. No intermittent fever in the preceding week
  • Part I: Change in Disability Over Time in the Child Health Assessment Questionnaire-Disability Index (CHAQ-DI) From Baseline to End of Part I [ Time Frame: Baseline, End of Part I (Week 32) ] [ Designated as safety issue: No ]
    The childhood health assessment questionnaire, CHAQ was used to assess physical ability and functional status of patients as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". Parents choose from four response categories, ranging from 0(without any difficulty) to 3(unable to do). A negative change indicates improvement.
  • Part II: Change in Disability Over Time by the Child Health Assessment Questionnaire-Disability Index (CHAQ-DI) [ Time Frame: Start of Part II (Week 32), End of Part II ( total duration-88 weeks) ] [ Designated as safety issue: No ]

    CHAQ-DI assessed physical ability and functional status of patients and quality of life. 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". Parents choose from 4 response categories, ranging from 0(without any difficulty) to 3(unable to do).

    Repeated measures Analysis of Covariance with treatment group, visit day, prednisone (or equivalent) dose and adapted ACR 70 response reached at the end of Part Id as covariates.

  • Part I: Change in Health Related Quality of Life Over Time by Child Health Questionnaire (CHQ-PF50) [ Time Frame: Baseline, End of Part I ( Week 32) ] [ Designated as safety issue: No ]
    The CHQ-PF50© is an instrument used to measure Health Related Quality of Life in children 5-18 from the parent's perspective. The questionnaire measures the following concepts: Physical functioning, Role/social emotional, Role/social behavior, Role/social physical, Bodily pain, General behavior, Mental health, Self-esteem, General health perception, Change in health, Parental impact - emotional, Parental impact - time, Family activities, and Family cohesion. Summaries are provided for Physical Health and Psychosocial Health. Scores range from 0-100. Increase in score represents improvement.
  • Part II: Change in Health Related Quality of Life Over Time by Child Health Questionnaire (CHQ-PF50) [ Time Frame: Start Part II (Week 32), End Part II (total duration - 88 Weeks) ] [ Designated as safety issue: No ]
    CHQ-PF50 measures Physical functioning, Role/social emotional, behavior and physical, Bodily pain, General behavior, Mental health, Self-esteem, General health perception, Change in health, Parental impact-emotional, Parental impact-time, Family activities and cohesion. Summaries are provided for Physical Health and Psychosocial Health. An increase in score indicates improvement. Repeated measures Analysis of Covariance change from start of Part II with treatment group, visit day, prednisone(or equivalent) dose and adapted ACR70 Pediatric response reached at the end of Part Id as covariates.
  • Maintenance of adapted ACR Pediatric 30/50/70/90/100 criteria during Part II [ Time Frame: During part II, which is event driven (total duration - TBD) ] [ Designated as safety issue: No ]
  • Change in disability over time by CHAQ [ Time Frame: Over the length of the event driven study (total duration - TBD) ] [ Designated as safety issue: No ]
  • Change in health related quality of life over time by CHQ-PF50 [ Time Frame: During part II, which is event driven (total duration - TBD) ] [ Designated as safety issue: No ]
  • Proportion of patients who reached a steroid dose < or = 0.2 mg/kg at end of Part Ic [ Time Frame: Maximum duration of Part I 32 weeks ] [ Designated as safety issue: No ]
  • Steroid level at end of Part Ic and change from baseline to end of Part Ic [ Time Frame: Maximum duration of Part I 32 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations

This two-part study assessed the sustained efficacy of canakinumab in the double-blind Part II and the ability to taper steroids in the open label Part I.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Systemic Juvenile Idiopathic Arthritis With Active Flare
  • Drug: canakinumab
    Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
  • Drug: placebo
    Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
  • Experimental: Canakinumab
    In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
    Intervention: Drug: canakinumab
  • Placebo Comparator: Placebo
    Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
    Intervention: Drug: placebo
Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ; PRINTO; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
177
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed diagnosis of systemic juvenile idiopathic arthritis as per International League Against Rheumatism (ILAR) definition that must have occurred at least 2 months prior to enrollment with onset of disease < 16 years of age.

    -Arthritis in one or more joints with or preceded by fever of at least 2 weeks duration that is documented to be daily for at least 3 days with accompanying symptoms

  • Active disease at the time of enrollment defined as follows:

    • At least 2 joints with active arthritis (using American College of rheumatology) ACR definition of active joint)
    • Documented spiking, intermittent fever (body temperature > 38oC) for at least 1 day during the screening period within 1 week before first study drug dose
    • C-reactive protein > 30 mg/L (normal range < 10 mg/L)
  • No concomitant use of second line agents such as disease-modifying and/ or immunosuppressive drugs will be allowed with the exception of:

    • Stable dose of methotrexate for at least 8 weeks prior to the screening visit, and/or folic/folinic acid per standard medical practice
    • Stable dose of no more than one non-steroidal anti-inflammatory drug for at least 2 weeks prior to the screening visit
    • Stable dose of steroid treatment < or = to 1.0 mg/kg/day in 1-2 doses per day of oral prednisone or equivalent

Exclusion criteria:

  • Diagnosis of active macrophage-activation syndrome (MAS) within the last 6 months
  • Risk factors for tuberculosis
  • Patients with active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of HIV infection, Hepatitis B and Hepatitis C infection

Other protocol inclusion/exclusion criteria may apply

Both
2 Years to 19 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Belgium,   Brazil,   Canada,   France,   Germany,   Hungary,   Israel,   Italy,   Netherlands,   Norway,   Peru,   Poland,   South Africa,   Spain,   Sweden,   Switzerland,   Turkey
 
NCT00889863
CACZ885G2301, EudraCT: 2008-005479-82
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Pediatric Rheumatology International Trials Organization
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP